Background: MAPT haplotypes are associated with PD, but their association with rapid eye movement sleep behavior disorder is unclear. Objective: To study the role of MAPT variants in rapid eye movement sleep behavior disorder. Methods: Two cohorts were included: (A) PD (n 5 600), rapid eye movement sleep behavior disorder (n 5 613) patients, and controls (n 5 981); (B) dementia with Lewy bodies patients with rapid eye movement sleep behavior disorder (n 5 271) and controls (n 5 950). MAPT-associated variants and the entire coding sequence of MAPT were analyzed. Age-, sex-, and ethnicity-adjusted analyses were performed to examine the association between MAPT, PD, and rapid eye movement sleep behavior disorder. Results: MAPT-H2 variants were associated with PD (odds ratios: 0.62-0.65; P 5 0.010-0.019), but not with rapid eye movement sleep behavior disorder. In PD, the H1 haplotype odds ratio was 1.60 (95% confidence interval: 1.12-2.28; P 5 0.009), and the H2 odds ratio was 0.68 (95% confidence interval: 0.48-0.96;
P 5 0.03). The H2/H1 haplotypes were not associated with rapid eye movement sleep behavior disorder. Conclusions: Our results confirm the protective effect of the MAPT-H2 haplotype in PD, and define its components. Furthermore, our results suggest that MAPT does not play a major role in rapid eye movement sleep behavior disorder, emphasizing different genetic background than in PD in this locus. V C 2018 International Parkinson and Movement Disorder Society Key Words: REM sleep behavior disorder; Parkinson's disease; genetics; MAPT Rapid eye movement (REM) sleep behavior disorder (RBD) is characterized by loss of muscle atonia and enactment of dreams during REM sleep. RBD will progress, in most cases, to an overt synucleinopathy; either Parkinson's disease (PD), dementia with Lewy bodies (DLB), or, rarely, multiple system atrophy (MSA). 1 Multiple genetic variants have been implicated in PD 2, 3 and some in DLB and MSA, 4 yet the potential role of most of them in RBD is still unknown.
Common genetic variation at the MAPT locus represent the second strongest genetic association in recent genome-wide association studies in PD, 2 and may also have a minor role in DLB. 5, 6 Recent studies in MSA also highlighted the MAPT H2 haplotype, although the small sample size precluded a genome-wide significant P value. 7, 8 Studies in PD focusing on the H1 and H2 MAPT haplotypes demonstrated that these haplotypes are associated with increased and decreased risk for PD, respectively, [9] [10] [11] and GWAS confirmed that the MAPT H2 haplotype was strongly associated with PD risk. 2 MAPT subhaplotype analysis and a sequencing study recently performed in DLB suggested that a rare subhaplotype, H1G, and a rare coding variant, p.A152T, were associated with DLB. 5, 6 However, a previous study in a large DLB cohort showed no evidence of association of the MAPT locus with DLB. 12 Overall, it seems that MAPT haplotypes play an important role in PD, whereas their role in MSA and DLB is still not clear, and could be minor. Given that RBD patients may convert to either PD or DLB, two studies have been recently performed to determine the association between MAPT and RBD. 13, 14 Both studies suggested a possible association; however, both studies were small and thus underpowered.
In the current study, we aimed to perform a thorough genetic study of the MAPT locus and its association with RBD (idiopathic RBD and RBD in DLB) and PD, using targeted next-generation sequencing (NGS) of the entire coding region of MAPT, and indepth haplotype analysis, in larger cohorts with RBD.
Patients and Methods

Study Population
Two Independent cohorts were included (Supplementary Table 1 ), and more details on their recruitment and diagnosis is in the Supplementary file: (A) The Montreal Neurological Institute cohort included 600 PD patients, 613 RBD patients, and 981 controls, all unrelated, of European ancestry. (B) The Mayo cohort included 271 patients with clinical DLB who were diagnosed with RBD and 950 controls. All participants in both cohorts signed an informed consent at enrollment to the study, and the respective ethical review boards approved the study protocols.
Genotyping
In cohort A, eight MAPT single-nucleotide polymorphisms (SNPs) were genotyped (Table 1) , including six MAPT locus haplotype-tagging SNPs and two additional MAPT SNP, which were previously reported to be associated with PD and RBD. 13, 14 In cohort B, the six haplotype-tagging SNPs were previously genotyped and reported. Further details on the genotyping are in the Supplementary file.
Targeted NGS
A subset of cohort A, including samples from 525 PD patients, 342 RBD patients, and 825 controls was sequenced using targeted NGS. The coding sequences of 51 PD-related genes (Supplementary Table 2 ), including MAPT, were captured using molecular inversion probes, as was previously described. 15 Further details on alignment, filtering, and analysis are in the Supplementary file.
Statistical Analysis
Full details on the statistical analysis can be found in the Supplementary file. To account for potential bias that may have occurred in cohort A, attributed to the different populations in patients and controls (despite all being of European origin), a principal component analysis (PCA) was performed. Goodnessof-fit chi-square test with one degree of freedom was performed to examine deviation from HardyWeinberg equilibrium (HWE) in the controls for each variant. Adjusted and unadjusted regression models were performed to examine the association between the tested SNPs and haplotypes in the MAPT locus and PD or RBD. Burden analysis was done as described in the Supplementary file. All analyses were performed with PLINK 1.9 or R.
Results
Association of MAPT SNPs With PD and RBD
Data on population stratification and adjustment is in the Supplementary file. Genotyping success rate of
the eight selected MAPT SNPs was 100% in both cohorts, and all variants were in HWE in the control group. An additional seven common variants with allele frequencies >0.05 were identified in the subset of samples from cohort A (525 PD patients, 342 RBD patients, and 825 controls) that underwent targeted NGS of MAPT. Logistic regression models, with and without adjustment for age, sex, and population principal components, were performed (Table 1) . Of the 15 common variants (Table 1) , seven H2-haplotype variants were in almost full linkage disequilibrium (rs12185268, rs8070723, rs1800547, rs62063786, rs62063787, rs17651549, and rs10445337), all associated with a reduced risk for PD (odds ratios [ORs]: 0.62-0.65; P 5 0.010-0.019, age, sex, and ethnicity adjusted). The two other H2-haplotye SNPs that were previously reported to be associated with RBD, rs12185268 and rs1800547, 13, 14 were not associated with RBD in the current study, nor were any of the other MAPT SNPs. In cohort B, rs7521 was nominally associated with DLB-RBD (OR, 1.24; 95% confidence interval [CI]: 1.02-1.52; P 5 0.035; Supplementary Table 3) ; however, it was not associated with RBD in cohort A. Burden analysis did not identify association between rare MAPT variants and PD or RBD (see Supplementary file).
Analysis of MAPT Haplotypes and Association
With Risk for PD and RBD
The H1 haplotype was associated with an increased risk for PD (OR, 1.60; 95% CI: 1.12-2.28; P 5 0.009), and the H2 haplotype was associated with a reduced risk for PD (OR, 0.68; 95% CI: 0.48-0.96; P 5 0.03). However, the H1 and H2 haplotype were not associated with RBD both in cohort A of idiopathic RBD patients and in cohort B with DLB-RBD. With the data from the targeted NGS, we demonstrate that the H2 haplotype includes eight coding variants ( Supplementary Fig. 2 ), which are all in full or almost full LD: p.P202L (rs63750417); p.D285N (rs62063786); p.R370W (rs17651549); p.S447P (rs10445337); p.P493P (rs1052551); p.T540T (rs62063845); p.A562A (rs1052553); and p.N590N (rs17652121).
Subsequently, we analyzed the H1 subhaplotypes to determine whether any of them is associated with PD or RBD ( Table 2) . A total of 20 H1 subhaplotypes with frequency > 0.01 were identified in cohort A, and 16 H1 subhaplotype with frequency > 0.01 were identified in cohort B. Two subhaplotypes, H1J and H1Z, were nominally associated with PD in the unadjusted analysis, but lost significance when adjusted for age, sex, and principal components. Similarly, the H1H and H1O were nominally associated with RBD in cohort A in the unadjusted model (data not shown), but lost significance after the adjustment for age, sex, and principal components. In cohort B, the previously reported DLB-associated haplotype H1G was associated with DLB-RBD (OR, 2.85; 95% CI: 1.30-6.27; P 5 0.009; Supplementary Table 4) . However, it was also associated with DLB without RBD (from cohort B, data not shown), and in cohort A, this haplotype had identical frequencies of 0.011 in RBD patients and controls (P 5 0.78; Table 2 ), suggesting that the association is driven by DLB and not by RBD.
Discussion
The current study increases our understanding of the role of MAPT haplotypes in PD and RBD by: (1) We confirm the association between MAPT H1/H2 haplotypes in PD, with an increased risk for H1 and decreased risk for H2. (2) MAPT is not associated with RBD, which provides further evidence for RBD having a different genetic background than PD, at least partially. (c) Our targeted NGS analysis defines the H2 haplotype, including several coding MAPT variants (nonsynonymous and synonymous, Supplementary Figure 2 ), although probably not expressed in the central nervous system (CNS). 16 The lack of association of MAPT with RBD suggests that RBD has a genetic background that does not fully overlap with that of PD. Whereas GBA mutations are associated with both PD and RBD, [17] [18] [19] previous studies had demonstrated that LRRK2 pathogenic mutations that may cause PD are not associated with RBD, 20, 21 and that PD patients with LRRK2 mutations had little or no RBD. 22, 23 In addition, the APOE E4 haplotype, which is strongly associated with Alzheimer's disease and DLB, was also not associated with RBD. 24 Therefore, RBD may represent a subtype of synucleinopathy with its own genetic background, but this hypothesis should be tested in larger cohorts by using whole-genome methods. Whether these genetic associations and lack thereof suggest lack of role for tauopathy in RBD should be examined by pathological studies of PD and DLB patients with and without RBD, as well as in idiopathic RBD.
The association of the H1/H2 haplotypes with PD is well defined across various populations. 2, 10, 11 Because this haplotype includes multiple, potentially regulatory noncoding variants, as well as coding synonymous and nonsynonymous variants, these data alone do not allow us to identify the specific variant that affects the risk within this haplotype. Exons 4a and 6, in which the nonsynonymous variants are found, are thought to not be expressed in the CNS. 16 However, because the peripheral nervous system is involved early at the course of PD, and may even be where PD begins, we cannot rule out a role for these variants in PD. 25 The current study has several limitations. The differences in age and sex of patients and controls can potentially bias results of age-related effects of genetic factors. However, we accounted for this potential bias by adjusting for both in the regression models. Similarly, there could be an effect of the different European populations; therefore, we further adjusted for the two top principal components of ethnicity as detected by PCA. Another potential limitation is the study size, despite being the largest genetic study on RBD, to the best of our knowledge. It is still possible that an association could only be observed in a larger cohort of patients and controls. Therefore, subsequent, larger studies are needed to further examine this association.
Overall, our data confirm the association of MAPT with PD, and suggest that MAPT genetic variants have Adjusted for age, sex, and the two major components in the population stratification PCA.
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minor or no role in RBD. Further studies are needed to replicate these results, and to examine the specific effects of variants within the H2 haplotype, but also other haplotypes, on PD risk and mechanism.
